Abstract
Cancer management needs rapid, non-invasive diagnosis and tumour-specific therapeutics which is unfortunately lacking for most cancer types. Novel approaches for cancer management aim at providing customized therapy according to individual diagnoses, determined by gene expression profiling, in particular, targeting highly selective monoclonal antibodies (mAbs) to single cancer cell antigens, in combination with highly cytotoxic drugs, thereby avoiding the unwanted side effects of conventional chemotherapy. Multifunctional nano-vectors that combine new and more powerful drugs and/or probes for diagnostic imaging with tumour surface-specific ligands/antibodies have been developed. These nano-vectors have displayed superior selective anti-tumour activity compared to antibodies or standard anti-cancer drugs/agents alone both in-vitro, and in preclinical and clinical models. Anti-cancer nano-platforms can significantly improve early cancer detection and ameliorate therapeutic strategies. In the immediate future nano-technology may enable the simultaneous early detection and selective inactivation of cancer cells before they develop into full blown tumours.
Keywords: Nano-vectors, cancer targeting, drug delivery, diagnosis, therapy.
Current Drug Metabolism
Title:Multifunctional Anti-Cancer Nano-Platforms are Moving to Clinical Trials
Volume: 14 Issue: 5
Author(s): Claudio Esposito, Annalisa Crema, Antonio Ponzetto, Giovanni Murtas and Guido Carloni
Affiliation:
Keywords: Nano-vectors, cancer targeting, drug delivery, diagnosis, therapy.
Abstract: Cancer management needs rapid, non-invasive diagnosis and tumour-specific therapeutics which is unfortunately lacking for most cancer types. Novel approaches for cancer management aim at providing customized therapy according to individual diagnoses, determined by gene expression profiling, in particular, targeting highly selective monoclonal antibodies (mAbs) to single cancer cell antigens, in combination with highly cytotoxic drugs, thereby avoiding the unwanted side effects of conventional chemotherapy. Multifunctional nano-vectors that combine new and more powerful drugs and/or probes for diagnostic imaging with tumour surface-specific ligands/antibodies have been developed. These nano-vectors have displayed superior selective anti-tumour activity compared to antibodies or standard anti-cancer drugs/agents alone both in-vitro, and in preclinical and clinical models. Anti-cancer nano-platforms can significantly improve early cancer detection and ameliorate therapeutic strategies. In the immediate future nano-technology may enable the simultaneous early detection and selective inactivation of cancer cells before they develop into full blown tumours.
Export Options
About this article
Cite this article as:
Esposito Claudio, Crema Annalisa, Ponzetto Antonio, Murtas Giovanni and Carloni Guido, Multifunctional Anti-Cancer Nano-Platforms are Moving to Clinical Trials, Current Drug Metabolism 2013; 14 (5) . https://dx.doi.org/10.2174/13892002113149990009
DOI https://dx.doi.org/10.2174/13892002113149990009 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Third and Fourth Generation Fluoroquinolone Antibacterials: A Systematic Review of Safety and Toxicity Profiles
Current Drug Safety Immunotoxicity and Immunogenicity of Biopharmaceuticals: Design Concepts and Safety Assessment
Current Drug Safety Allergy to Miscellaneous Household Arthropods
Protein & Peptide Letters Hypersensitivity Reactions to Neuromuscular Blocking Agents
Current Pharmaceutical Design Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy Design, Development and Optimization of Ramipril Solid Lipid Nanoparticles Using Solvent Emulsification and Evaporation Method
Nanoscience & Nanotechnology-Asia Non-glycemic Adverse Effects of Insulin
Current Diabetes Reviews Safety and Efficacy of Aliskiren in the Treatment of Hypertension and Associated Clinical Conditions
Current Drug Safety Natriuretic Peptide Family: New Aspects
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Antagonists of Endothelin Receptors: Results and Perspectives
Current Pharmaceutical Analysis Editorial (Hot Topic: Inflammation, Coagulation, Vascular Permeability and Thrombosis)
Current Vascular Pharmacology Chronic Spontaneous Urticaria: Epidemiological Characteristics Focusing on the Histocompatibility Profile and Presence of Antibodies
Inflammation & Allergy - Drug Targets (Discontinued) Role of ARBs in the Blood Hypertension Therapy and Prevention of Cardiovascular Events
Current Drug Targets Pharmacological Interactions on Blood Pressure Control in Arterial Hypertension, An Issue not to be Overlooked
Cardiovascular & Hematological Disorders-Drug Targets Children with Chronic Kidney Disease and Hypertension: Could Hypertension Footprints be Early Biomarkers?
Current Hypertension Reviews Histamine and Histamine Receptor Antagonists in Cancer Biology
Inflammation & Allergy - Drug Targets (Discontinued) Intravenous Immunoglobulin as a Potential Therapy for Refractory Urticaria - A Review
Inflammation & Allergy - Drug Targets (Discontinued) Hypertension in Hemodialysis Patients
Current Hypertension Reviews Biologic Agents in the Treatment of Psoriasis
Recent Patents on Inflammation & Allergy Drug Discovery Effects of Natural Products on Contact Dermatitis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents